Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581787 · ClinicalTrials.gov registry record · Phase 1
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Maximilian Diehn.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02581787 is a Phase 1 study that has completed, run by Maximilian Diehn. The registered enrollment target is 28 participants.
The verdict
NCT02581787, a Phase 1 study, has completed, sponsored by Maximilian Diehn.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The SABR-ATAC trial (Stereotactic Ablative Radiotherapy and anti-TGFB Antibody Combination) is a phase I/II trial that studies the side effects and efficacy of fresolimumab, an anti-transforming growth factor beta (TGFB) antibody, when given with stereotactic ablative radiotherapy in patients with stage IA-IB non-small cell lung cancer. Fresolimumab may inhibit radiation side effects and block tumor growth through multiple mechanisms. Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy (SBRT), is a specialized form of radiation therapy that precisely delivers high dose radiation directly to tumors, thus killing tumor cells and minimizing damage to normal tissue. Giving fresolimumab with SABR may work better in treating patients with early stage non-small cell lung cancer than treating with SABR alone.
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- BIOLOGICAL Fresolimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-08 |
| Est. Completion | 2023-03-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581787
The ClinicalTrials.gov registry entry for NCT02581787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maximilian Diehn, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT02581787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02581787 about?
NCT02581787 is a clinical study titled "SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer". The SABR-ATAC trial (Stereotactic Ablative Radiotherapy and anti-TGFB Antibody Combination) is a phase I/II trial that studies the side effects and efficacy of fresolimumab, an anti-transforming growth factor beta (TGFB) antibody, when given with stereotactic ablative radiotherapy in patients with s...
What is the current status of trial NCT02581787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-08. Estimated completion is 2023-03-02.
What interventions are being tested in trial NCT02581787?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Fresolimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02581787?
This trial is sponsored by Maximilian Diehn, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.